US patients given first dose of coronavirus antibody treatment

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Patients have been given the first dose of a potential antibody treatment designed to fight coronavirus&period;<&sol;p>&NewLine;<p>Scientists developed the antibody in just three months after identifying it from blood taken from one of the first American patients to recover from Covid-19&period;<&sol;p>&NewLine;<p>The immune system produces antibodies to fight off foreign invaders when it detects infection&period;<&sol;p>&NewLine;<p>This medicine&comma; referred to as LY-CoV555&comma; emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of coronavirus&period;<&sol;p>&NewLine;<p>Researchers say it is the first potential new medicine specifically designed to attack SARS-CoV-2&comma; the virus that causes Covid-19&period;<&sol;p>&NewLine;<p>The first patients in the study were given the medication at major medical centres in the US including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles&period;<&sol;p>&NewLine;<p>The placebo-controlled study will assess safety and tolerability in patients hospitalised with with the disease&comma; and results are expected by the end of June&period;<&sol;p>&NewLine;<p>A single dose of the medicine is administered via IV to up to 32 participants&period;<&sol;p>&NewLine;<p>Mark Mulligan&comma; director of the Division of Infectious Diseases and Immunology and director of the Vaccine Center at NYU Langone Health&comma; said&colon; &OpenCurlyDoubleQuote;<i>We are committed to working with our industry partners to generate scientific evidence to meet the urgent need for treatments that reduce the severity of Covid-19 disease&period;<&sol;i>”<&sol;p>&NewLine;<p>He added&colon; &OpenCurlyDoubleQuote;<i>Antibody treatments like the one being studied here hold promise to be effective medical countermeasures against this deadly infection&period;<&sol;i>”<&sol;p>&NewLine;<p>Daniel Skovronsky&comma; Lilly’s chief scientific officer and president of Lilly Research Laboratories&comma; said&colon; &OpenCurlyDoubleQuote;<i>Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of Covid-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems&period;<&sol;i>”<&sol;p>&NewLine;<p>If the Phase 1 results show the antibody can be safely administered&comma; researchers will move on to start studying LY-CoV555 in non-hospitalised Covid-19 patients&period;<&sol;p>&NewLine;<p>Eli Lilly and Company also plans to study the drug in a preventative setting&comma; focusing on vulnerable patient populations who historically are not optimal candidates for vaccines&period;<&sol;p>&NewLine;<p>AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases &lpar;NIAID&rpar; identified the antibody&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68e2fe8a8b64f">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68e2fe8a8b64f'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version